Plain-English translation of NCT07914933 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a medication called levosimendag given during surgery can help your heart pump better after you have surgery to remove chronic blood clots from your lungs. Researchers want to see if this medication reduces pressure in the arteries around your lungs and helps your heart function improve during recovery.
After clot-removal surgery, some patients still have high pressure in their lung arteries and their heart doesn't recover as well as hoped. Doctors don't have a proven treatment for this complication yet, so this trial is testing whether this medication might help prevent or reduce this problem.
You likely qualify if…
You likely don't qualify if…
You would receive either the study medication or a placebo (inactive infusion) through an IV during your scheduled lung clot-removal surgery—you won't know which one you're getting. Researchers will monitor your heart function, lung artery pressure, and recovery in the days right before, during, and after your surgery to see if the medication helps.
AI-generated summary from trial data · Nov 15, 2026 · Not medical advice
Russia
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Enrollment target
~50 participants
Started
April 2025
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gleb Moroz, PhD
Meshalkin Research Institute of Pathology of Circulation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.